Part of the solution could be providing more information to the public. Low public awareness of the New Delhi project is thought to have contributed to opposition [25] , and the Cartagena Protocol requires that signatories facilitate public awareness of GMOs and their use [15] . However, despite efforts to inform the local community before trialling GM mosquitoes in Grand Cayman in 2009 [28] , there were subsequently complaints that the international research community was not adequately consulted [28, 29] , highlighting the importance of engaging with all stakeholders and not just beneficiaries. More recently, attempts to inform the public about GM mosquito releases in Brazil did not prevent the spread of conspiracy theories linking them to the emergence of Zika virus [30] [31] [32] .
It is also important that communication is two-way. The "knowledge deficit" model of science communication is increasingly recognised as outdated [33] , partly because public concerns are not always obvious. In the UK, discussion at recent public and parliamentary events on the use of GM insects for disease control organised by the authors [34, 35] suggested that concerns were higher where private companies were involved than for public sector research. Elsewhere in Europe, it has been suggested that, although public debate around GMOs often focuses on possible biological risks, actual concerns may be about the economic consequences of their use [26] . If true, this could create a vicious cycle: public mistrust of GM driven by its concentration in the hands of a few companies could encourage policymakers to make the licensing and approval process more restrictive, driving up regulatory costs and excluding small companies [14] . However, the views of the most vocal opponents of GM do not necessarily represent views held at a population level [36, 37] .
Given the lessons learned so far, we suggest that the following three areas represent the best compromise between proportionate risk assessment and maximising the potential benefits of GM.
Firstly, assessments should regulate product, not process. Currently, the EU regulates by process, meaning that mosquitoes rendered sterile by radiation, genetic modification, or the addition of symbiotic bacteria such as Wolbachia [38, 39] would be regulated differently and potentially by a different agency. Product-based regulation works effectively in countries such as Canada.
Secondly, assessments should consider the balance of risk and benefit resulting from GM insect release, not risk alone. Currently, the EU only considers risk (as discussed above), preventing applicants from providing information on the benefits of the proposed technology [40] . Risk assessment should consider the risks of inaction (status quo) as well as those of proposed action and realistic alternatives such as insecticides [41] .
Finally, the process of assessment needs to be more transparent. This would allow both beneficiaries and stakeholders to take part in better-informed discussions of proposed products and the results of trial studies, encourage consistent assessment by authorities across multiple regions, and make it clear to the public that assessments receive expert scrutiny, building confidence in the process. At the same time, we recognise that requiring full disclosure of methods and data at the time of application would strongly discourage innovation. Possible compromises could be to only release data from successful assessments, to embargo these data for a period after the assessment is approved, and/or to consider some form of market exclusivity for a period in return for such disclosure.
Issues relating to the optimal balance between risk and benefit for the use of GM insects for disease control are not going away. New technologies are making it easier and faster to develop GM insects [42] . Although appropriate risk assessment is necessary for novel technologies, focusing assessment on poorly defined biological risks for which there may be no plausible mechanism discourages small companies and academic organisations from developing transgenic insect technologies. The suggestions above could accelerate risk assessment without
